Growth-hormone-releasing Hormone (ghrh) Or Derivative Patents (Class 514/11.2)
  • Patent number: 10918730
    Abstract: Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also described are pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such analogs or salts thereof, as well as methods, kits and uses thereof, for example for inducing or stimulating growth hormone secretion in a subject and for diagnosing, preventing or treating GH-deficient conditions in a subject.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: February 16, 2021
    Assignee: GRIFFON PHARMACEUTICALS INTERNATIONAL SA
    Inventor: Krishna G. Peri
  • Patent number: 10829516
    Abstract: The present invention concerns compositions comprising and methods of identification and use of imaging agents. The imaging agents comprise a growth hormone secretagogues having a conjugated fluoride. The imaging agents of the present invention may be used for detection, diagnosis and/or staging of prostate or other forms of cancer, and may also be used for cardiac disease.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 10, 2020
    Assignee: LONDON HEALTH SCIENCES CENTRE RESEARCH INC.
    Inventors: Leonard G. Luyt, Milan Mrazek Fowkes
  • Patent number: 10563174
    Abstract: Disclosed herein are bacterial proteins that increase pancreatic beta (?) cell number and/or proliferation, methods of increasing ? cell number and/or proliferation using such proteins, and methods of treating or inhibiting diabetes in a subject by administering such proteins to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as any one of SEQ ID NOs: 1-7, or fragments thereof. Recombinant vectors including a nucleic acid encoding the protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to any one of SEQ ID NOs: 1-7 or fragments thereof) operably linked to a heterologous promoter are also disclosed. Also disclosed are methods of identifying compounds that increase ? cell number and/or proliferation by determining the effect of test compounds on ? cell number or proliferation in zebrafish pancreas.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 18, 2020
    Assignee: University of Oregon
    Inventors: Jennifer Hampton, Karen Guillemin
  • Patent number: 10550377
    Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: February 4, 2020
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventors: Frederic Madec, Philip Lecane, Philip Marks, Keith Foster
  • Patent number: 9409948
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: August 9, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • Patent number: 9096684
    Abstract: The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: August 4, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Noriyuki Kawahata, Vincent Guerlavais, Manoj Samant
  • Patent number: 9079974
    Abstract: There are provided a novel series of peptide analogs of hGH-RH(1-29)NH2 and hGH-RH(1-30)NH2 which show high activities in stimulating the release of pituitary GH in animals. They retain their physiological activity in solution for extended periods of time and resist enzymic degradation in the body. These novel and useful properties appear to be due to novel substitution patterns ant at the 1, 15, 27 and 29 positions on the peptide.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 14, 2015
    Assignees: The University of Miami, The United States of America, represented by the Department of Veterans Affairs
    Inventors: Andrew V Schally, Ren Zhi Cai, Marta Zarandi
  • Patent number: 8980249
    Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: March 17, 2015
    Assignees: University of Miami, Dresden University of Technology
    Inventors: Andrew V. Schally, Barbara Ludwig, Stefan Bornstein, Norman L. Block
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20150031615
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 29, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventor: Zheng Xin DONG
  • Publication number: 20150011864
    Abstract: A method for preventing cognitive decline, comprises the steps of identifying, in an individual, a first stage of cognitive decline corresponding to Subjective Cognitive Impairment and administering a predetermined treatment to the individual to inhibit a progression of the individual to a second predetermined stage of cognitive decline or to inhibit progression of cognitive decline within the first stage.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 8, 2015
    Inventor: Barry Reisberg
  • Publication number: 20140378380
    Abstract: The present invention relates to methods for protecting a subject, tissues and/or organs from a subject against oxidative stress-induced damage, such as but not limited to, oxidative stress-induced tissue damage. The method comprises administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Inventors: Maria Felice Brizzi, Ezio Ghigo
  • Publication number: 20140323402
    Abstract: The present invention relates to water-soluble protein carrier-linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier-linked prodrugs, their use as a medicament as well as methods of treatment and administration.
    Type: Application
    Filed: August 10, 2012
    Publication date: October 30, 2014
    Applicant: Ascendis Phama A/S
    Inventors: Ulrich Hersel, Dirk Vetter
  • Publication number: 20140249083
    Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a ?-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn8, are also disclosed.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 4, 2014
    Applicant: THERATECHNOLOGIES INC.
    Inventors: Kirill I Shingel, Daniel Fleury
  • Publication number: 20140193378
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat diabetes. In one embodiment, a method of promoting survival of grafted cells and/or tissues may involve exposing the cells and/or tissues to an effective amount of at least one agonist of GHRH. In some embodiments, the grafted cells and/or tissues may be pancreatic cells. In some embodiments, the grafted cells may be islet cells co-cultured with non-pancreatic cells. In a further embodiment, a method of treating a patient diagnosed with diabetes involves transplanting and/or grafting the islet cells and/or tissues comprising islet cells into a patient, and administering a therapeutically effective amount of at least one agonist of GHRH to the patient. In some embodiments, the islet cells and/or tissues comprising islet cells may be optionally exposed to GHRH and/or at least one agonist of GHRH prior to transplantation into a patient.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 10, 2014
    Applicants: UNIVERSITY OF MIAMI, DRESDEN UNIVERSITY OF TECHNOLOGY, U.S.A., REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Andrew V. SCHALLY, Norman L. BLOCK, Stefan BORNSTEIN, Barbara LUDWIG
  • Publication number: 20140179604
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Application
    Filed: December 23, 2013
    Publication date: June 26, 2014
    Applicants: U.S.A., REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF MIAMI
    Inventors: Andrew V. SCHALLY, Joshua M. HARE, Norman L. BLOCK, Samirah A. GOMES, Rosemeire M. KANASHIRO-TAKEUCHI
  • Patent number: 8691942
    Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.
    Type: Grant
    Filed: September 25, 2010
    Date of Patent: April 8, 2014
    Assignees: University of Miami, U.S.A. Represented by the Dept. of Veterans Affairs
    Inventors: Andrew V. Schally, Marta Zarandi, Jozsef L. Varga, Ren Zhi Cai
  • Publication number: 20140057847
    Abstract: Disclosed herein are methods demonstrating that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 ?g/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function. Whereas, both JI-38 and GH augmented levels of cardiac precursor cell proliferation, only JI-38 increased anti-apoptotic gene expression. Collectively, these findings demonstrate that within the heart, GHRH-agonists can activate cardiac repair following MI.
    Type: Application
    Filed: July 22, 2013
    Publication date: February 27, 2014
    Applicants: United States of America, Represented by The Department of Veterans Affairs, University of Miami
    Inventors: Andrew V. SCHALLY, Norman L. Block, Joshua M. Hare, Rosemeire Miyuki Kanashiro-Takeuchi
  • Patent number: 8633151
    Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: January 21, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen
  • Publication number: 20130261055
    Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 96) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.
    Type: Application
    Filed: September 25, 2010
    Publication date: October 3, 2013
    Inventors: Andrew V. Schally, Marta Zarandi, Jozsef L. Varga, Ren Zhi Cai
  • Publication number: 20130261058
    Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
    Type: Application
    Filed: September 16, 2011
    Publication date: October 3, 2013
    Applicants: University of Miami, U.S. Department of Veterans Affairs, National and Kapodistrian University of Athens
    Inventors: Andrew V. Schally, Hippokratis Kiaris, Norman L. Block
  • Publication number: 20130230598
    Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.
    Type: Application
    Filed: February 20, 2013
    Publication date: September 5, 2013
    Applicant: LG LIFE SCIENCES, LTD., INC.
    Inventors: Myung-Jin KIM, Sun-Jin KIM, Oh-Ryong KWON
  • Patent number: 8507433
    Abstract: Whether the growth hormone (GH)/Insulin-like growth factor 1(IGF-I) axis exerts cardioprotective effects remains controversial; and the underlying mechanism(s) for such actions are unclear. Here we tested the hypothesis that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 ?g/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: August 13, 2013
    Assignees: University of Miami, The United States of America, represented by the Deptartment of Veterans Affairs
    Inventors: Andrew V. Schally, Norman L Block, Joshua Hare, Rosemeire Miyuki Kanashiro Takeuchi
  • Publication number: 20130195807
    Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
    Type: Application
    Filed: June 3, 2011
    Publication date: August 1, 2013
    Inventors: Andrew V. Schally, Barbara Ludwig, Stefan Bornstein, Norman L. Block
  • Patent number: 8481489
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: July 9, 2013
    Assignee: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
  • Patent number: 8450268
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: May 28, 2013
    Assignee: Tranzyme Pharma Inc.
    Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
  • Publication number: 20130123169
    Abstract: The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.
    Type: Application
    Filed: October 18, 2012
    Publication date: May 16, 2013
    Applicant: Aileron Therapeutics, Inc.
    Inventor: Aileron Therapeutics, Inc.
  • Publication number: 20130123170
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: January 4, 2013
    Publication date: May 16, 2013
    Applicant: Ipsen Pharma, S.A.S.
    Inventor: Ipsen Pharma, S.A.S.
  • Patent number: 8435945
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: May 7, 2013
    Assignee: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
  • Patent number: 8431534
    Abstract: Human growth hormone factor (GFR) containing pharmaceutical compositions are described, and more precisely, lyophilized compositions of hGRF stabilized by means of saccharose.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: April 30, 2013
    Assignee: Merck Serono SA
    Inventors: Fabrizio Samaritani, Alessandra Del Rio
  • Publication number: 20130101514
    Abstract: Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat nephropathy, and methods for preparing activated fatty acids are provided herein.
    Type: Application
    Filed: October 10, 2012
    Publication date: April 25, 2013
    Applicant: Complexa, Inc.
    Inventor: Complexa, Inc.
  • Publication number: 20130052237
    Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
    Type: Application
    Filed: August 29, 2012
    Publication date: February 28, 2013
    Applicant: INTARCIA THERAPEUTICS, INC.
    Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
  • Patent number: 8361964
    Abstract: Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: January 29, 2013
    Assignee: Theratechnologies Inc.
    Inventors: Krishna G. Peri, Abdelkrim Habi
  • Patent number: 8334256
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: December 18, 2012
    Assignee: Tranzyme Pharma Inc.
    Inventors: Eric Marsault, Carl St-Louis
  • Patent number: 8318664
    Abstract: A method for treating obesity and more particularly a method for treating diet-induced obesity in a subject comprising administering to said subject an isolated unacylated ghrelin peptide as set forth in SEQ ID NO: 1, a fragment thereof or a cyclic fragment thereof such as a cyclic unacylated ghrelin fragment. The method being achievable without affecting the food intake of the subject.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: November 27, 2012
    Assignee: Alize Pharma SAS
    Inventor: Aart Jan Van Der Lely
  • Patent number: 8314066
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: November 20, 2012
    Assignee: Theratechnologies Inc.
    Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
  • Publication number: 20120270784
    Abstract: Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system.
    Type: Application
    Filed: April 17, 2012
    Publication date: October 25, 2012
    Applicant: THERATECHNOLOGIES INC.
    Inventors: Krishna G. Peri, Abdelkrim Habi
  • Publication number: 20120156164
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Application
    Filed: September 2, 2010
    Publication date: June 21, 2012
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Ki-Dong Park, Yoon-ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20120148529
    Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.
    Type: Application
    Filed: May 12, 2010
    Publication date: June 14, 2012
    Applicants: Centro de Invesigacion Biomedica en Red en Bioiagenieria, Biomateriales, y Nanomedicina (Cibe, Universitat Autonoma de Barcelona et al.
    Inventors: Elena Garcia-Fruitos, Esther Vazquez Gomez, Jose Luis Corchero, Antonio Pedro Villa Verde Corrales
  • Patent number: 8188056
    Abstract: One aspect of the current invention is a method of preventing and/or treating arthritis and/or preventing or treating lameness in a subject. Additionally, subject quality of life and welfare, and body condition scores are improved by utilizing methodology that administers the nucleic acid expression construct encoding a GHRH or functional biological equivalent to a subject through a parenteral route of administration. Following a single dose of nucleic acid expression vector, subjects are healthier and effects are demonstrated long term without additional administration(s) of the expression construct.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: May 29, 2012
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Ruxandra Draghia-Akli, Patricia A. Brown, David Hood
  • Publication number: 20120108511
    Abstract: The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues.
    Type: Application
    Filed: October 13, 2011
    Publication date: May 3, 2012
    Applicant: QLT USA, INC.
    Inventors: Lester Moore, Richard L. Norton
  • Publication number: 20120087859
    Abstract: The present invention relates to a biopolymer-modified nanocarrier in which chitosan is bound to a water-soluble biocompatible polymer that has been crosslinked via a photo-crosslinkable functional group; wherein the chitosan-modified nanocarrier has a diameter which changes in accordance with changes in temperature, has enhanced skin permeability or cellular uptake and selective delivery to cancer tissue as compared with a bare nanocarrier to which chitosan has not been bound, and exhibits characteristics that are advantageous in photothermal therapy. The chitosan-modified nanocarrier of the present invention exhibits highly superior efficacy as a transdermal carrier, since the skin permeability is enhanced to a significant level as compared with a bare nanocarrier that has no chitosan.
    Type: Application
    Filed: January 21, 2011
    Publication date: April 12, 2012
    Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Gi Yoong Tae, Won II Choi, Young Ha Kim, Ja-Young Kim, Jong Hyun Lee
  • Publication number: 20120087891
    Abstract: The present invention relates biomedically useful compositions containing bioactive agents and biodegradable carbohydrate polyethers that exhibit reverse thermogelation properties in aqueous media. The microstructure structure and properties of the carbohydrate polyethers can be conveniently controlled with respect to functionality, molecular weight, polydispersity index, microstructure and tertiary structure, they can be customized for use in a variety of biomedical applications including drug delivery, cell delivery, surgical procedures and the like.
    Type: Application
    Filed: October 10, 2011
    Publication date: April 12, 2012
    Inventor: Alexander A. Gorkovenko
  • Publication number: 20120045430
    Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 23, 2012
    Inventors: Dan Luo, Yougen Li
  • Publication number: 20120027879
    Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
    Type: Application
    Filed: August 3, 2011
    Publication date: February 2, 2012
    Inventor: Harry A. DUGGER, III
  • Publication number: 20120004174
    Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
    Type: Application
    Filed: July 7, 2011
    Publication date: January 5, 2012
    Applicant: THERATECHNOLOGIES INC.
    Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
  • Publication number: 20110195097
    Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
    Type: Application
    Filed: April 20, 2011
    Publication date: August 11, 2011
    Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
  • Publication number: 20110135596
    Abstract: A transmembrane fusion protein including ubiquitin or a ubiquitin-like protein, a membrane translocation sequence linked to the C-terminus of the ubiquitin or ubiquitin-like protein, and a biologically active molecule linked to the C-terminus of the membrane translocation sequence is disclosed herein. A polynucleotide encoding the transmembrane fusion protein, a recombinant expression vector including the polynucleotide sequence, a cell transformed by the recombinant expression vector, and a method of delivering the biologically active molecule into a cell using the transmembrane fusion protein are also disclosed.
    Type: Application
    Filed: December 3, 2010
    Publication date: June 9, 2011
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jae-il LEE, Tae-soo LEE, Young-sun LEE
  • Publication number: 20110117184
    Abstract: Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.
    Type: Application
    Filed: January 20, 2011
    Publication date: May 19, 2011
    Inventors: Philip James Bromley, Lee Nickols Huang
  • Patent number: 7943575
    Abstract: The invention features a method of administering one or more therapeutic agents to a patient and delivering said agent or agents continuously over an extended period of time, said method comprising: obtaining a pharmaceutical composition including a peptide carrier, one or more therapeutic agents, and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier; and parenterally administering said pharmaceutical composition to a subject by injection, wherein said composition automatically forms a gel after interaction with the patient's bodily fluids and releases said peptide carrier and said agent or agents continuously within the patient over an extended period.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: May 17, 2011
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Jacques-Pierre Moreau, Roland Cherif-Cheikh